



New York State Correctional Officers & Police Benevolent Association

102 Hackett Boulevard - Albany, NY 12209
(518) 427-1551 www.nyscopba.org nyscopba@usa.net



TO: NYSCOPBA Chief Sector Stewards

FROM: Sharon Smith, Health Benefits Specialist

DATE: November 18, 2019

RE: Empire Plan's Prescription Drug Advanced Flexible Formulary
Changes for 2020

As you know, changes to the Empire Plan's Prescription Drug Advanced Flexible Formulary can be made once a year, effective the new plan year. Below are the changes for 2020.

A total of 13 drugs will be added to the list of exclusions; 3 drugs will move up a tier; 57 drugs will move down a tier; and 2 drugs previously excluded on the formulary will be added to coverage at Tier 2. Specifics are as follows:

Exclusions:

Drug Name

Use

Actemra SQ	Various Autoimmune Conditions
Armonair RespiClick	Asthma
Fulphila	Neutropenia (Low White Blood Cells)
Ilumya	Psoriasis
Insulin Lispro	Diabetes (High Blood Sugar)
Insulin Lispro KwikPen	Diabetes (High Blood Sugar)
Norpace CR	Heart Arrhythmia
Olumiant	Rheumatoid Arthritis
Orencia SQ	Various Autoimmune Conditions
Procrit	Anemia (Low Red Blood Cells)
Rinvoq	Rheumatoid Arthritis
Skyrizi	Psoriasis
Zarxio	Neutropenia (Low White Blood Cells)

Uptier:

Alrex	Topical Ophthalmic
Durezol	Topical Ophthalmic
Lazanda	Analgesics –Transmucosal Fentanyl

Downtiers:

Drug Name

Use

Abstral	Analgesics – Transmucosal Fentanyl
Acuvail	Topical Ophthalmic
Adempas	Cardiovascular – Pulmonary Arterial Hypertension
Adynovate	Hematologic – Hemophilia A
Ajovy	Central Nervous System – Migraine
Aralast NP	Respiratory – Alpha 1 Antitrypsin Deficiency
Aristada Initio	Central Nervous System- Antipsychotics
Arnuity Ellipta	Respiratory – Corticosteroid Inhalers
Austedo	Central Nervous System – Movement Disorders
Bevespi Aerosphere	Respiratory – Anticholinergic/Beta Agonist Inhalers
Climara Pro	Endocrine & Metabolic – Estrogens/ Progestins
Corlanor	Cardiovascular – Chronic Heart Failure
Divigel	Endocrine & Metabolic – Estrogens
Dupixent	Respiratory – Severe Asthma
Emgality	Central Nervous System - Migraine
Emverm	Anti-Infectives - Anthelmintic
Estring	Endocrine & Metabolic – Estrogens
Eucrisa	Topical Dermatology – Immunomodulators
Evamist	Endocrine & Metabolic – Estrogens
Eylea	Topical Ophthalmic –Retinal Disorders
Fasenra	Respiratory – Severe Asthma
FML Forte	Topical Ophthalmic
FML Sop	Topical Ophthalmic
Ilevro	Topical Ophthalmic
Ingrezza	Central Nervous System – Movement Disorders
Jivi	Hematologic – Hemophilia A
Kovaltry	Hematologic – Hemophilia A
Kyleena	Endocrine & Metabolic – Contraceptives
Lastacaft	Topical Ophthalmic
Lokelma	Endocrine & Metabolic – Potassium Removing Agents
Lucentis	Topical Ophthalmic –Retinal Disorder
Mayzent	Central Nervous System – Multiple Sclerosis

Downtiers Continued:

<u>Drug Name</u>	<u>Use</u>
Mulpleta	Hematologic – Thrombocytopenia
Namzaric	Central Nervous System - Antidementia
Neulasta	Hematologic – Neutropenia CSF Long Acting
Nivestym	Hematologic – Neutropenia CSF Short
Novoeight	Hematologic – Hemophilia A
Nucala	Respiratory – Severe Asthma
Nuwiq	Hematologic – Hemophilia A
Orilissa	Endocrine & Metabolic - Endometriosis
Pred Mild	Topical Ophthalmic Acting
Prolastin C	Respiratory – Alpha 1 Antitrypsin Deficiency
Rebinyn	Hematologic – Hemophilia B
Retacrit	Hematologic – Hematopoietic Growth Factors
Rhopressa	Topical Ophthalmic –Rho Kinase Inhibitors
Rocklatan	Topical Ophthalmic – Rho Kinase Inhibitors
Ruconest	Hematologic – Hereditary Angioedema
Stiolto Respimat	Respiratory – Anticholinergic/Beta Agonist Inhalers
Striverdi Respimat	Respiratory – Laba Inhalers
Toviaz	Genitourinary – Urinary Antispasmodics
Trelegy Ellipta	Respiratory – ICS/Laba/Lama Combination Inhalers
Udenyca	Hematologic – Neutropenia CSF Long Acting
Veltassa	Endocrine & Metabolic – Potassium Removing Agents
Vemlidy	Anti-Infectives – Anthelmintic
Xolair	Respiratory – Severe Asthma
Xtampza ER	Analgesics – CII Chronic
Zohydro ER	Analgesics – CII Chronic

Drugs from Exclusions Added Back on Formulary at Tier 2:

Humatrope	Human Growth Hormones
Zembrace Symtouch	Central Nervous System –Migraine

November 18, 2019

Page 4

As a result of the changes, a total of 1 member will be affected by the exclusions; 12 members will be affected by drug uptiers; and 133 members will be affected by the downtiers.

Disruption letters are mailed to those members affected by the excluded drugs. Participating providers in the Empire Plan will receive the 2020 Advanced Flexible Formulary around the same time. Affected members should speak with their provider regarding their scripts and possible alternatives.

Should you have any questions, feel free to contact me.

ss

cc: NYSCOPBA Executive Board
NYSCOPBA Jt. Committee on Health Benefits